Weekly Neurology Deep Dive - A review of recent impactful publications in the field of Neurology

This academic review proposes a unified spectrum model for multiple sclerosis (MS) that challenges traditional, rigid phenotype classifications like RRMS, SPMS, and PPMS. The authors argue that disability often accumulates through progression independent of relapse activity (PIRA) and "smouldering" disease processes, which frequently occur silently long before a formal progressive diagnosis. By integrating the role of neurologic reserve and biological ageing, the text explains how the clinical transition to progressive states reflects a declining capacity to compensate for ongoing tissue injury rather than a brand-new disease mechanism. This shift toward a biology-aware framework aims to facilitate earlier recognition of worsening and move treatment strategies beyond a simple focus on suppressing acute relapses. Ultimately, the source advocates for longitudinal, multidimensional monitoring to better address the continuous pathological evolution that shapes long-term neurological decline across the entire MS continuum.

This epiode is an extended version of the recently published episode on the examination and localization of eye movement disorders. The orginal paper details a comprehensive clinical framework for the examination and localization of eye movement disorders, emphasizing that the systematic bedside assessment serves as the primary tool for anatomical diagnosis. By distinguishing between supranuclear, nuclear, and infranuclear lesions, clinicians can categorize ocular motor dysfunction based on how specific eye movements, such as saccades or the vestibulo-ocular reflex, are impacted. The sources outline essential quantitative bedside tools—including prism cover tests and the HINTS battery—to differentiate between vascular, inflammatory, and degenerative causes. Detailed profiles of various conditions are provided, ranging from cranial nerve palsies and brainstem stroke syndromes to complex neuromuscular junction disorders like myasthenia gravis. Ultimately, the text illustrates how specific findings, such as pupillary involvement or fatigability, help narrow a wide differential into a precise neurological or structural diagnosis. This episode is based on a paper written exclusively for the Weekly Neurology Deep Dive Podcast by Amer A. Ghavanini MD PhD FRCPC.

This episode is a comprehensive review of a peper exploring the 2024 McDonald criteria, which represent a significant update to the global standards for diagnosing multiple sclerosis (MS). These revisions aim to facilitate earlier diagnosis and improve clinical outcomes by incorporating new paraclinical tools, such as optic nerve imaging, central vein sign, and kappa free light chains. For the first time, the criteria provide formal diagnostic pathways for asymptomatic individuals and those with atypical symptoms who exhibit characteristic MRI findings. The document also emphasizes strategies to avoid misdiagnosis, particularly in pediatric populations and older adults with vascular comorbidities. Furthermore, the authors address the practical challenges of global implementation, advocating for increased education and technological access in resource-limited settings.

This umbrella review evaluates the clinical efficacy and safety of two recently approved anti-amyloid antibodies, lecanemab and donanemab, for treating early-stage Alzheimer’s disease. By synthesizing data from eleven high-quality systematic reviews and meta-analyses, the authors conclude that these drugs successfully reduce brain amyloid burden and provide a statistically significant slowing of cognitive decline. However, the text highlights a critical concern: the observed cognitive benefits often fall below established clinically meaningful thresholds, suggesting that patients might not perceive a significant improvement in daily life. Furthermore, both treatments are associated with an increased risk of amyloid-related imaging abnormalities (ARIA), such as brain edema and hemorrhage, particularly in ApoEε4 gene carriers. Consequently, the source emphasizes that prescribing these therapies requires rigorous patient selection, careful monitoring through regular MRIs, and transparent communication regarding the modest expected outcomes. Ultimately, while these antibodies represent a significant pharmacological shift in dementia care, their benefits must be carefully weighed against potential safety risks and high financial costs.

This paper provides a comprehensive clinical framework for the examination and localization of eye movement disorders, emphasizing that the systematic bedside assessment serves as the primary tool for anatomical diagnosis. By distinguishing between supranuclear, nuclear, and infranuclear lesions, clinicians can categorize ocular motor dysfunction based on how specific eye movements, such as saccades or the vestibulo-ocular reflex, are impacted. The sources outline essential quantitative bedside tools—including prism cover tests and the HINTS battery—to differentiate between vascular, inflammatory, and degenerative causes. Detailed profiles of various conditions are provided, ranging from cranial nerve palsies and brainstem stroke syndromes to complex neuromuscular junction disorders like myasthenia gravis. Ultimately, the text illustrates how specific findings, such as pupillary involvement or fatigability, help narrow a wide differential into a precise neurological or structural diagnosis. This episode is based on a paper written exclusively for the Weekly Neurology Deep Dive Podcast by Amer A. Ghavanini MD PhD FRCPC.